)
Valneva (VLA) investor relations material
Valneva Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Total revenues for the first nine months of 2025 reached €127.0 million, up 8.9% year-over-year, with product sales of €119.4 million and strong IXIAROⓇ/JESPECTⓇ and IXCHIQⓇ performance despite headwinds.
Operating cash burn was significantly reduced to €28.4 million from €76.7 million, supporting a cash position of €143.5 million at period end, including €26.2 million from ATM transactions.
Debt refinancing was completed, extending maturity to Q4 2030 and enhancing financial flexibility.
Net loss was €65.2 million, compared to a net profit of €24.7 million in 2024, which included a one-time gain from a Priority Review Voucher sale.
Key business highlights included responses to disease outbreaks, new contracts, and regulatory progress for multiple vaccines.
Financial highlights
Product sales were €119.4 million, up 6.2% year-over-year; IXIAROⓇ/JESPECTⓇ sales rose 12.5% to €74.3 million, and IXCHIQⓇ sales increased 330% to €7.6 million.
DUKORALⓇ sales decreased to €21.5 million, impacted by currency and distributor transition in Germany.
Gross margin on commercial products (excluding IXCHIQⓇ) improved to 57.2% from 48.6% year-over-year.
Operating loss was €53.9 million versus a €34.2 million profit last year, which included a €90.8 million one-time gain from a priority review voucher sale.
Adjusted EBITDA was negative €37.7 million, compared to positive €48.6 million last year.
Outlook and guidance
Full-year 2025 product sales guidance confirmed at €155–€170 million; total revenues expected at €165–€180 million.
R&D expenses projected at €80–€90 million, partially offset by grants and tax credits.
Commercial business expected to be cash-flow positive, with lower operational cash burn and focus on maintaining sufficient runway to key milestones.
Midterm expectations include continuous product sales growth, strategic R&D investment, and improved gross margin.
Sustainable profitability anticipated post-approval and commercialization of the Lyme disease vaccine, potentially from 2027.
Next Valneva earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage